New possibilities in anticoagulant management of atrial fibrillation

Reviews in Cardiovascular Medicine

Volumn 5, Issue SUPPL. 5, 2004, Pages

  Waldo, Albert L ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Anticoagulation; Atrial fibrillation; Stroke; Systemic embolism; Warfarin; Ximelagatran

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ANTICOAGULANT AGENT; BILIRUBIN; CLOPIDOGREL; ERYTHROMYCIN; IDRAPARINUX; IRBESARTAN; PLACEBO; WARFARIN; XIMELAGATRAN;

ARTICLE; BLEEDING; CLINICAL TRIAL; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MONITORING; FOOD DRUG INTERACTION; HEART ATRIUM FIBRILLATION; HIGH RISK POPULATION; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; LIVER DYSFUNCTION; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SINUS RHYTHM; STROKE; THROMBOEMBOLISM;

ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; AZETIDINES; BENZYLAMINES; CEREBROVASCULAR ACCIDENT; HUMANS; OLIGOSACCHARIDES; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE; WARFARIN;

EID: 12344291864     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Go AS, Hylek EM, Phillips KA, et al, for the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention. JAMA. 2001;285:2370-2375.
2. Waldo AL. Stroke prevention in atrial fibrillation. JAMA 2003;209:1093-1095.
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med. 1987;147:1561-1564.
4. Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med. 1995;155:469-473.
5. Petersen P, Masden EB, Brun B, et al. Silent cerebral infarction in chronic atrial fibrillation [abstract]. Stroke. 1987;18:1098-1100.
6. Guidotti M, Tadeo G, Zanasi S, Pellegrini G. Silent cerebral ischemia in patients with chronic atrial fibrillation: a case-control study. Irish J Med Sci. 1990;159:96-97.
7. Feinberg WM, Seeger JF, Carmody RF, et al. Epidemiologic features of asymptomatic cerebral infarction in patients with nonvalvular atrial fibrillation [abstract]. Arch Intern Med. 1990;150:2340-2344.
8. Ezekowitz MD, James KE, Nazarian SM, et al, for the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Silent cerebral infarction in patients with nonrheumatic atrial fibrillation. Circulation. 1995; 92:2178-2182.
9. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449-1457.
10. Atwood JE, Albers GW. Anticoagulation and atrial fibrillation. Herz. 1993;18:27-38.
11. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol. 2002; 38:1231-1266.
12. Hart RG, Pearce LA, Rothbart RM, et al. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. J Am Coll Cardiol. 2000;35:183-187.
13. Ezekowitz MD, Levine JA. Preventing stroke in patients with atrial fibrillation. JAMA. 1999;281:1830-1835.
14. Gage BF, Waterman AM, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001; 285:2864-2870.
15. Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA. 2003;290:1049-1056.
16. Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. Chest. 2002;119:225-385.
17. Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and therapeutic range. Chest. 2001;119:8S-21S.
18. Stafford RS, Singer DE. National patterns of warfarin use in atrial fibrillation. Arch Intern Med. 1996;156:2537-2541.
19. Go AS, Hylek EM, Borowsky LH, et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Ann Intern Med. 1999;131:927-934.
20. Bo S, Cicone G, Scaglione L, et al. Warfarin for non-valvular atrial fibrillation: still underused in the 21st century? Heart. 2003;89:553-554.
21. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994 120:897-902.
22. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003;349:1019-1026.
23. Petersen P, Grind M, Adler J. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: SPORTIF II: A dose-guiding, tolerability and safety study. J Am Coll Cardiol. 2003;41:1445-1451.
24. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996;335:540-546.
25. van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA. 2002;288:2441-2448.
26. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131:492-501.
27. SPAF Investigators. A differential effect of aspirin in prevention of stroke on atrial fibrillation. J Stroke Cerebrovasc Dis. 1993;3:181-188.
28. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;34:1825-1833.
29. Bhandari AK, Anderson JL, Gilbert M, et al, and the Flecainide Supraventricular Tachycardia Study Group. Correlation of symptoms with occurrence of paroxysmal supraventricular tachycardia or atrial fibrillation: a transtelephonic monitoring study. Am Heart J. 1992; 124:381-386.
30. Page RL, Wilkerson WE, Clark WK, et al. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation. 1994;89:224-227.
31. Savelieva I, Camm AJ. Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management. J Intervent Cardiac Electrophysiol. 2000;4:369-382.
32. Israel C, Ehrlich JR, Gronefeld G, et al. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optional patient care. J Am Coll Cardiol. 2004;43:47-52.
33. National Institutes of Health/National Library of Medicine. A safety and efficacy trial evaluating the use of SanOrg34006 compared to warfarin or acenocoumaril in patients with atrial fibrillation. Available at: www.clinicaltrials.gov.
34. Hohnloser SH, Connolly SJ. Combined antiplatelet therapy in atrial fibrillation: review of the literature and future avenues. J Cardiovasc Electrophysiol. 2003;14(9 Suppl): 560-563.
35. SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomized controlled trial. Lancet 2003;362:1691-1698.
36. Halperin J for the SPORTIF V Investigators. SPORTIF V: Stroke Prevention Using Oral Thrombin Inhibitor in Atrial Fibrillation V. Presented at the Scientific Sessions of the American Heart Association; November 9-12, 2003; Orlando, FL.
37. Eriksson UG, Bredberg V, Hoffman KJ, et al. Absorption, distribution, metabolism and excretion of ximelagatran, an oral direct thrombin inhibitor in rats, dogs, and humans. Drug Metab Dispos. 2003;31:294-305.
38. Sarich TC, Wolzt M, Eriksson UG, et al. Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. J Am Coll Cardiol. 2003;41:557-564.
39. Bergsrud EA, Ghandi PJ. A review of the clinical uses of ximelagatran in thrombosis syndromes. J Thromb Thrombolysis. 2003;16:175-188.
40. Woltz W, Willbratt M, Svensson M, et al. Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects. Eur J Clin Pharmacol. 2003; 59:537-543.
41. Dorani H, Schutzer K, Sarich TC, et al. Effect of erythromycin on the pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran and its active form melagatran [abstract]. Clin Pharmacol Therapeut. 2004;75:78.
42. Data on file, AstraZeneca.
43. Olsson SB for the SPORTIF III Investigators. Stroke prevention using the oral direct thrombin inhibitor ximelagatran, compared with dose-adjusted warfarin in patients with non-valvular atrial fibrillation (SPORTIF III). Presented at the European Society of Cardiology Congress. September 2, 2003. Vienna, Austria.